

Rimas V Lukas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6870510/publications.pdf>

Version: 2024-02-01

106
papers

2,749
citations

236925

25
h-index

206112

48
g-index

113
all docs

113
docs citations

113
times ranked

4260
citing authors

#	ARTICLE	IF	CITATIONS
1	Hemangioblastoma diagnosis and surveillance in von Hippel-Lindau disease: a consensus statement. <i>Journal of Neurosurgery</i> , 2022, 136, 1511-1516.	1.6	8
2	Leptomeningeal metastases: the future is now. <i>Journal of Neuro-Oncology</i> , 2022, 156, 443-452.	2.9	11
3	Leptomeningeal metastases—What outcomes should we measure and how?. <i>Neuro-Oncology</i> , 2022, 24, 1736-1737.	1.2	3
4	What is New in Neuro-oncology?. <i>Neurologic Clinics</i> , 2021, 39, 163-179.	1.8	3
5	Long-term outcomes of spinal ependymomas: an institutional experience of more than 60 cases. <i>Journal of Neuro-Oncology</i> , 2021, 151, 241-247.	2.9	9
6	Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab045.	0.7	4
7	Complete Bilateral Hippocampal Diffusion Restriction and Reversible Amnesia Following Opiate, Cocaine, and Benzodiazepine Abuse. <i>Cureus</i> , 2021, 13, e12651.	0.5	5
8	Commentary: Long-Term Outcomes of Intra-Arterial Chemotherapy for Progressive or Unresectable Pilocytic Astrocytomas: Case Studies. <i>Neurosurgery</i> , 2021, 88, E343-E344.	1.1	0
9	A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	136
10	Establishment of an acute headache infusion clinic as an alternative for emergency department care. <i>Journal of the Neurological Sciences</i> , 2021, 423, 117384.	0.6	0
11	The Spinal Dural Arteriovenous Fistula in a Patient With Metastatic Renal Cell Carcinoma. <i>Cureus</i> , 2021, 13, e15303.	0.5	0
12	Gene Therapy for the Treatment of Malignant Glioma. <i>Advances in Oncology</i> , 2021, 1, 189-202.	0.2	3
13	Tumor type, epilepsy burden, and seizure documentation: experiences at a single center neuro-oncology clinic. <i>Neuro-Oncology Practice</i> , 2021, 8, 581-588.	1.6	0
14	Essential oils for blood-brain barrier disruption: Preclinical studies of NEO100 in breast cancer brain metastases. <i>Neuro-Oncology</i> , 2021, 23, 1621-1622.	1.2	1
15	Introduction to the evolving landscape of the management of glioblastoma. <i>Chinese Clinical Oncology</i> , 2021, 10, 34-34.	1.2	0
16	An international perspective on the management of glioblastoma. <i>Chinese Clinical Oncology</i> , 2021, 10, 40-40.	1.2	0
17	Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. <i>Lancet Oncology</i> , The, 2021, 22, 1103-1114.	10.7	91
18	Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 6514-6528.	7.0	48

#	ARTICLE	IF	CITATIONS
19	Glioblastoma as an age-related neurological disorder in adults. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab125.	0.7	30
20	American Society of Clinical Oncology 2021 Annual Meeting updates on primary brain tumors and CNS metastatic tumors. <i>Future Oncology</i> , 2021, 17, 4425-4429.	2.4	0
21	ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. <i>Nature Cancer</i> , 2021, 2, 1372-1386.	13.2	39
22	Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. <i>Neuro-Oncology</i> , 2020, 22, 470-479.	1.2	49
23	Clinical neuro-oncology for the neurologist. <i>Neurology: Clinical Practice</i> , 2020, 10, 458-465.	1.6	5
24	Newly diagnosed enhancing lesions: Steroid initiation may impede diagnosis of lymphoma involving the central nervous system. <i>Journal of Clinical Neuroscience</i> , 2020, 81, 61-64.	1.5	3
25	Is Next-Generation Sequencing Alone Sufficient to Reliably Diagnose Gliomas?. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 763-766.	1.7	6
26	Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice. <i>Journal of Neuro-Oncology</i> , 2020, 148, 489-500.	2.9	38
27	Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 5232-5245.	7.0	52
28	Acute Neurological Complications of Brain Tumors and Immune Therapies, a Guideline for the Neuro-hospitalist. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 32.	4.2	0
29	Commentary: Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons. <i>Neurosurgery</i> , 2020, 87, E289-E290.	1.1	0
30	Leptomeningeal metastasis from solid tumors. <i>Journal of the Neurological Sciences</i> , 2020, 411, 116706.	0.6	34
31	Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma?. <i>Journal of Neurosurgery</i> , 2020, 132, 1667-1672.	1.6	10
32	Commentary: BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction with Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study. <i>Neurosurgery</i> , 2019, 84, 881-882.	1.1	1
33	Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	170
34	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. <i>Neuro-Oncology</i> , 2019, 21, 1498-1508.	1.2	49
35	Immunotherapy Against Gliomas: is the Breakthrough Near?. <i>Drugs</i> , 2019, 79, 1839-1848.	10.9	10
36	Pleomorphic xanthoastrocytoma: a brief review. <i>CNS Oncology</i> , 2019, 8, CNS39.	3.0	53

#	ARTICLE	IF	CITATIONS
37	The interplay among psychological distress, the immune system, and brain tumor patient outcomes. <i>Current Opinion in Behavioral Sciences</i> , 2019, 28, 44-50.	3.9	22
38	Neurooncology Research in Nigeria: Great Untapped Potential. <i>World Neurosurgery</i> , 2019, 124, 381-385.	1.3	7
39	Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. <i>Nature Medicine</i> , 2019, 25, 462-469.	30.7	569
40	The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma. <i>Frontiers in Pharmacology</i> , 2019, 10, 200.	3.5	82
41	Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. <i>Lung Cancer</i> , 2019, 128, 105-112.	2.0	126
42	Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod. <i>Journal of Neuro-Oncology</i> , 2019, 141, 111-120.	2.9	24
43	Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017). <i>OncImmunology</i> , 2019, 8, 1548242.	4.6	1
44	Newly Diagnosed Glioblastoma: A Review on Clinical Management. <i>Oncology</i> , 2019, 33, 91-100.	0.5	42
45	Diagnostic Evaluation in Primary CNS Lymphoma. <i>Neurologist</i> , 2018, 23, 53-54.	0.7	6
46	IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 2559-2573.	7.0	147
47	Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system. <i>Neuro-Oncology</i> , 2018, 20, 1197-1206.	1.2	27
48	Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. <i>Epilepsy and Behavior</i> , 2018, 80, 331-336.	1.7	78
49	Delayed leptomeningeal metastasis of an adult anaplastic pilocytic astrocytoma. <i>Brain Tumor Pathology</i> , 2018, 35, 123-126.	1.7	1
50	<i>BRAF</i> inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma. <i>CNS Oncology</i> , 2018, 7, CNS10.	3.0	9
51	Hospital volume and group expertise in newly diagnosed glioblastoma management. <i>Journal of Neuro-Oncology</i> , 2018, 136, 213-214.	2.9	2
52	ATIM-15. A PHASE 1 STUDY OF Ad-RTS-hIL-12 + VELEDIMEX IN ADULTS WITH RECURRENT GLIOBLASTOMA: DOSE DETERMINATION WITH UPDATED OVERALL SURVIVAL. <i>Neuro-Oncology</i> , 2018, 20, vi3-vi4.	1.2	2
53	IMMU-34. A BALANCED TRYPTOPHAN DIET LEADS TO MAXIMAL IMMUNOTHERAPEUTIC EFFICACY IN GLIOBLASTOMA MODELS. <i>Neuro-Oncology</i> , 2018, 20, vi128-vi128.	1.2	0
54	QOLP-11. QUALITY OF LIFE IN HIGH-GRADE GLIOMA PATIENTS ON A PHASE I VIROTHERAPY STUDY. <i>Neuro-Oncology</i> , 2018, 20, vi216-vi216.	1.2	1

#	ARTICLE	IF	CITATIONS
55	QOLP-25. QUALITY OF LIFE FOLLOWING RE-IRRADIATION FOR RECURRENT HIGH GRADE GLIOMA. Neuro-Oncology, 2018, 20, vi220-vi220.	1.2	2
56	IMMU-41. IDO1 INCREASES Treg RECRUITMENT INDEPENDENT OF TRYPTOPHAN METABOLISM IN A MODEL OF GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi130-vi130.	1.2	0
57	HOUT-10. SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI) TREATMENT IS ASSOCIATED WITH IMPROVED SURVIVAL AMONG ELDERLY PATIENTS DIAGNOSED WITH GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi115-vi115.	1.2	0
58	IMMU-46. GLIOBLASTOMA PATIENT DIAGNOSES AND IMMUNOSUPPRESSION ARE MAXIMAL DURING OLD AGE: A RANDOM COINCIDENCE, OR CAUSE AND EFFECT?. Neuro-Oncology, 2018, 20, vi131-vi131.	1.2	0
59	IMMU-35. PSYCHOSOCIAL STRESS NEGATIVELY IMPACTS IMMUNOTHERAPY IN IMMUNOCOMPETENT MODELS OF GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi128-vi129.	1.2	0
60	INNV-21. AN OVERVIEW OF NIGERIAN NEURO-ONCOLOGY SCHOLARLY OUTPUT. Neuro-Oncology, 2018, 20, vi142-vi142.	1.2	0
61	IMMU-10. RADIOTHERAPY AND PD-1 BLOCKADE INCREASES TRYPTOPHAN METABOLISM IN BRAIN TUMOR-DRAINING SECONDARY LYMPHOID ORGANS. Neuro-Oncology, 2018, 20, vi123-vi123.	1.2	0

62

#	ARTICLE	IF	CITATIONS
73	Ambulatory training in neurology education. <i>Journal of the Neurological Sciences</i> , 2017, 372, 506-509.	0.6	4
74	Buzz Juice: Neurological sequelae of synthetic cannabinoids. <i>Journal of Clinical Neuroscience</i> , 2017, 37, 43.	1.5	4
75	Perceptions of clinical neurosciences among trainees in Wuhan, China. <i>Future Neurology</i> , 2017, 12, 65-70.	0.5	1
76	Added diagnostic utility of PET in a patient with subacute encephalopathy and small-cell lung cancer. <i>Lung Cancer Management</i> , 2017, 6, 9-16.	1.5	0
77	State-of-the-art considerations in small cell lung cancer brain metastases. <i>Oncotarget</i> , 2017, 8, 71223-71233.	1.8	47
78	Case Report of Bone Marrow-Sparing Proton Therapy Craniospinal Irradiation for Central Nervous System Myelomatosis. <i>Cureus</i> , 2017, 9, e1885.	0.5	8
79	Why neurology? Factors which influence career choice in neurology. <i>Neurological Research</i> , 2016, 38, 10-14.	1.3	17
80	Paraneoplastic epilepsy. <i>Epilepsy and Behavior</i> , 2016, 61, 51-58.	1.7	31
81	Breadth versus volume: Neurology outpatient clinic cases in medical education. <i>Journal of Clinical Neuroscience</i> , 2016, 28, 20-23.	1.5	6
82	Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. <i>Future Oncology</i> , 2016, 12, 1045-1058.	2.4	10
83	IMCT-21UPDATES ON PHASE 1B/2 COMBINATION STUDY OF THE IDO PATHWAY INHIBITOR INDOXIMOD WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH TEMOZOLOMIDE-REFRACTORY PRIMARY MALIGNANT BRAIN TUMORS. <i>Neuro-Oncology</i> , 2015, 17, v112.2-v112.	1.2	7
84	Treatment of leptomeningeal carcinomatosis: Current challenges and future opportunities. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 632-637.	1.5	46
85	Society for Neuro-Oncology 2014 annual meeting updates on central nervous system metastases. <i>Neuro-Oncology Practice</i> , 2015, 2, 57-61.	1.6	1
86	ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1978-1979.	1.5	6
87	The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1964-1968.	1.5	61
88	Structure of neuroscience clerkships in medical schools and matching in neuromedicine. <i>Neurology</i> , 2015, 85, 172-176.	1.1	36
89	Anti-N-methyl-D-aspartate-receptor encephalitis: diagnosis, optimal management, and challenges. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 517.	2.0	63
90	Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus. <i>Case Reports in Clinical Pathology</i> , 2014, 1, 151-154.	0.0	10

#	ARTICLE	IF	CITATIONS
91	Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches. <i>CNS Oncology</i> , 2014, 3, 61-75.	3.0	9
92	Treatment of Brain Metastases. <i>Oncology</i> , 2014, 87, 321-329.	1.9	20
93	Assessment of neurological clinical management reasoning in medical students. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 919-922.	1.5	6
94	Attitudes Toward Neurosciences in Medical Students in Wuhan, China: A Survey Study. <i>World Neurosurgery</i> , 2014, 82, 266-269.	1.3	17
95	Leptomeningeal carcinomatosis from breast cancer treated with intrathecal topotecan with concomitant intravenous eribulin. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1250-1251.	1.5	8
96	Clinical Neuro-Oncology Formal Education Opportunities for Medical Students in the United States and Canada. <i>World Neurosurgery</i> , 2014, 82, 938-944.	1.3	3
97	Update in the Treatment of High-grade Gliomas. <i>Neurologic Clinics</i> , 2013, 31, 847-867.	1.8	9
98	Teaching Video Neuro <i>Images</i> : Myokymia and nerve hyperexcitability as components of Morvan syndrome due to malignant thymoma. <i>Neurology</i> , 2013, 80, e55.	1.1	4
99	Etoposide and Temozolomide in Combination for the Treatment of Progressive Small-Cell Lung Cancer Central Nervous System Metastases: Two Cases. <i>Tumori</i> , 2013, 99, e73-e76.	1.1	1
100	Multicenter Analysis Of Primary Central Nervous System Lymphoma: Patient Characteristics, Treatment Patterns and Survival. <i>Blood</i> , 2013, 122, 1803-1803.	1.4	0
101	Etoposide and temozolomide in combination for the treatment of progressive small-cell lung cancer central nervous system metastases: two cases. <i>Tumori</i> , 2013, 99, e73-6.	1.1	1
102	Student assessment by objective structured examination in a neurology clerkship. <i>Neurology</i> , 2012, 79, 681-685.	1.1	23
103	Two Automobile Collisions in One Day. <i>Journal of Emergency Medicine</i> , 2012, 43, e263-e264.	0.7	0
104	Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage. <i>Journal of Clinical Neuroscience</i> , 2012, 19, 1310-1311.	1.5	1
105	Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases. <i>Journal of Neurology Research</i> , 2012, 2, 1-9.	0.5	7
106	Emerging therapies for malignant glioma. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, S29-S36.	2.4	13